Clinical trial

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

NCT01937689

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-01-01

PhasePHASE1

Study timeline

Study start (actual)2013-01-01Date precision: month

Registry last updated2018-07-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

PyrotinibDRUG

Sponsors & collaborators

Jiangsu HengRui Medicine Co., Ltd.lead sponsor

Chinese Academy of Medical Sciencescollaborator

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01937689 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.